The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-24
DOI
10.3389/fphar.2021.604928
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
- (2020) Daisuke Sueta et al. CURRENT HYPERTENSION REPORTS
- Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction
- (2020) Patrick Rossignol et al. EUROPEAN JOURNAL OF HEART FAILURE
- Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
- (2020) George L. Bakris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart failure drug treatment
- (2019) Patrick Rossignol et al. LANCET
- Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
- (2019) Jonatan Barrera-Chimal et al. KIDNEY INTERNATIONAL
- Barriers to guideline mandated renin–angiotensin inhibitor use: focus on hyperkalaemia
- (2019) Shilpa Vijayakumar et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study
- (2019) Sadayoshi Ito et al. JOURNAL OF HUMAN HYPERTENSION
- Associations between serum potassium and adverse clinical outcomes: a systematic literature review
- (2019) Eirini Palaka et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta‐analysis
- (2019) Chao Zuo et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- DOCA/Salt
- (2019) Elise P. Gomez-Sanchez JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease
- (2019) Maria-Eleni Alexandrou et al. JOURNAL OF HYPERTENSION
- The global burden of kidney disease and the sustainable development goals
- (2018) Valerie A Luyckx et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists
- (2018) Marco Trevisan et al. EUROPEAN JOURNAL OF HEART FAILURE
- Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients
- (2017) Phisitt Vejakama et al. BMC Nephrology
- The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology
- (2016) A. Loupy et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease
- (2015) Amanda H. Anderson et al. ANNALS OF INTERNAL MEDICINE
- PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy
- (2013) Stephen Orena et al. Frontiers in Pharmacology
- Cardiorenal disease development under chronic renin–angiotensin–aldosterone system suppression
- (2012) Pantelis A Sarafidis et al. JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM
- Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats
- (2010) Nicole Schupp et al. FASEB JOURNAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now